Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Sanofi (SNY) over the last 11 years, with Q4 2025 value amounting to $1.7 billion.

  • Sanofi's Receivables - Other rose 1150.36% to $1.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year increase of 1150.36%. This contributed to the annual value of $1.7 billion for FY2025, which is 686.81% up from last year.
  • Sanofi's Receivables - Other amounted to $1.7 billion in Q4 2025, which was up 1150.36% from $1.5 billion recorded in Q4 2024.
  • Sanofi's 5-year Receivables - Other high stood at $1.7 billion for Q4 2025, and its period low was $920.9 million during Q4 2021.
  • Its 5-year average for Receivables - Other is $1.4 billion, with a median of $1.5 billion in 2024.
  • As far as peak fluctuations go, Sanofi's Receivables - Other soared by 4280.63% in 2022, and later plummeted by 81.98% in 2024.
  • Quarter analysis of 5 years shows Sanofi's Receivables - Other stood at $920.9 million in 2021, then soared by 42.81% to $1.3 billion in 2022, then grew by 18.47% to $1.6 billion in 2023, then fell by 0.82% to $1.5 billion in 2024, then increased by 11.5% to $1.7 billion in 2025.
  • Its last three reported values are $1.7 billion in Q4 2025, $1.5 billion for Q4 2024, and $1.6 billion during Q4 2023.